News and Announcements
Shivom Raises $33 Million, Nearly Reaching Their Goal of $35 Million!
- Published April 25, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom raised $33 million during the course of our private and publicpresales
- Shivom is $2 million away from achieving the target cap
- Their public presale is still open and the bonus has been locked at 3% until the sale closes on Friday, April 27th, 6 PM GMT
We have exciting news to share with our community.
Shivom has raised $33 million during the course of our private and publicpresales, and is only $2 million away from achieving the target cap of $35 million. This is HUGE for us, and we cannot thank our contributors and partners enough for supporting us along the way.
CONSIDERING THAT, WE HAVE REMOVED THE MINIMUM CAP ON INVESTMENT FOR THE PRESALE NOW.
Our public presale is still open and the bonus has been locked at 3% until the sale closes on Friday, April 27th, 2018, 6 PM GMT. This is the last chance to make use of the available bonuses if you are still contemplating your contribution to join the Shivom community. Don’t miss your chance to be part of a global healthcare revolution.
To register, sign up at: https://tokensale.shivom.io/
KYC verification can take some time. However, please complete your purchase of OMIX tokens now. You’ll have enough time to complete your KYC verification post the Presale.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
